OUR PRODUCT OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% OMIDRIA® OMIDRIA, Omeros’ PharmacoSurgery® product, is a first-of-kind drug approved both in the US and in Europe to prevent miosis in cataract surgery and to reduce postoperative pain. OMIDRIA has been shown to reduce complications, to prevent intraoperative floppy iris syndrome (IFIS), and to reduce the need for opioids, pupil-expansion devices and postoperative steroids. LEARN MORE INDICATIONS AND USAGE OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. IMPORTANT SAFETY INFORMATION OMIDRIA must be added to irrigating solution prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma. The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. Please see the Full Prescribing Information for OMIDRIA. You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Related Pages PUBLICATIONS PATIENTS ©2020 Omeros Corporation, All rights reserved. Site Map Contact Us Privacy Policy Legal We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. If you continue to browse this site, you will accept our use of cookies. For more information, please read our Privacy Policy. AGREE